AQST Q4 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M+9.7% YoY

Gross Profit

-$34M-264.2% margin

Operating Income

-$29M-221.6% margin

Net Income

-$32M-244.8% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$160M

Total Liabilities

$194M

Stockholders' Equity

-$34M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$12M	+9.7%
Gross Profit	-$34M	$7M	-568.1%
Operating Income	-$29M	-$14M	-112.4%
Net Income	-$32M	-$17M	-86.8%

Revenue Segments

Manufacture and Supply Revenue

$12M92%

License and Royalty Revenue

$852,0007%

Co-Development and Research Fees

$181,0001%

Geographic Segments

UNITED STATES

$9M72%

Non-US

$4M28%